Companies: 10,795·Total market cap: $144.5T
Restart Life Sciences Corp.

Restart Life Sciences Corp.

NMLSFOTCHealthcare● Active
$0.04
+$0.00(+0.00%)
Market Cap$1279264
P/E Ratio—
52W High$0.12422
52W Low$0.0101
Cash on HandFinancialsRevenue

Restart Life Sciences Corp. (NMLSF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

NMLSF · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$1.7M▲ +872.4% vs prior year
FY · as of Dec 31, 2025 · Reported in CAD
Cash & Cash Equiv. (CCE)
$1.6M
cashAndCashEquivalents
Short-Term Investments
$53,528
shortTermInvestments
YoY Change vs Prior Year
+872.4%
vs prior fiscal year
Latest Quarter
$1.2M
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in CAD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$1.7MCash on Hand
Total Debt$245,359Total Debt
Net Cash / Net Debt+$1.4MNet Cash Position
Cash vs Debt Ratio
Cash 87%Debt 13%

Restart Life Sciences Corp. has a net cash position of $1.4M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$1.7M − $245,359 = +$1.4M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
NMLSF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$1.7M+872.4%
Dec 31, 2024$0.2M+2001.3%
Dec 31, 2023$0.0M-97.0%
Dec 31, 2022$0.3M+21.8%
Dec 31, 2021$0.2M-89.8%
NMLSF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.5%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.5%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Restart Life Sciences Corp.
Restart Life Sciences Corp.YOU
NMLSF
$1.7M129.2%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Restart Life Sciences Corp. (NMLSF) cash on hand as of December 31, 2025 is $1.7M, comprising $1.6M in cash and cash equivalents (CCE) plus $53,528 in short-term investments — reported as Restart Life Sciences Corp. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Restart Life Sciences Corp. cash reserves or cash position.

Restart Life Sciences Corp. annual cash on hand history shows increased +872.4% in 2025: increased +872.4% in 2025. Restart Life Sciences Corp. cash reserves in 2025 reflect the company's capital allocation strategy.

Restart Life Sciences Corp. carries total debt of $245,359 against cash of $1.7M, resulting in a net cash position of +$1.4M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

NMLSF cash on hand · 5 questions

As of December 31, 2025, Restart Life Sciences Corp. (NMLSF) has $1,652,577 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $1,599,049 in cash and cash equivalents (CCE) plus $53,528 in short-term investments. Latest quarter (March 31, 2026): $1,192,282. Data sourced from the annual 10-K filing via FMP.

NMLSF cash on handNMLSF cash reservesNMLSF cash 2025how much cash does NMLSF have

▸ Source: FMP /balance-sheet-statement · US GAAP · Restart Life Sciences Corp. · Restart Life Sciences Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025